Results 71 to 80 of about 852 (91)

Ceroid lipofuscinosis type 2 disease: Effective presymptomatic therapy-Oldest case of a presymptomatic enzyme therapy. [PDF]

open access: yesEur J Neurol
Breuillard D   +11 more
europepmc   +1 more source

Proximity labeling reveals non-catalytic interactions between DPP9 and ubiquitin signaling complexes. [PDF]

open access: yesCell Mol Life Sci
Wirtgen VE   +10 more
europepmc   +1 more source

Role of IPF genetic risk loci in post-COVID-19 lung abnormalities: a cohort study. [PDF]

open access: yesBMJ Open Respir Res
Marinescu DC   +9 more
europepmc   +1 more source

Intraventricular Cerliponase Alfa Treatment in a Patient with Advanced Neuronal Ceroid Lipofuscinosis Type 2. [PDF]

open access: yesIntern Med
Nakashima S   +9 more
europepmc   +1 more source

Identification and functional characterization of regulatory variants in DPP9 associated with COVID-19 severity. [PDF]

open access: yesGenome Med
Farah G   +10 more
europepmc   +1 more source

The Caenorhabditis elegans DPF-3 and Human DPP4 Have Tripeptidyl Peptidase Activity [PDF]

open access: yesFEBS Letters
The dipeptidyl peptidase IV (DPPIV) family comprises serine proteases classically defined by their ability to remove dipeptides from the N‐termini of substrates, a feature that gave the family its name. Here, we report the discovery of a previously unrecognized tripeptidyl peptidase activity in DPPIV family members from two different species.
Aditya Trivedi, Rajani Kanth Gudipati
exaly   +3 more sources
Some of the next articles are maybe not open access.

Related searches:

Home - About - Disclaimer - Privacy